Hsa_circ_0002320: a novel clinical biomarker for colorectal cancer prognosis

Abstract

A great many circular RNAs (circRNAs) exist in different types of mammalian cells. Previous studies have verified that a low level of hsa_circ_0002320 is present in gastric cancer and that it might represent a good prognostic indicator. However, its value in colorectal cancer (CRC) is unclear. The aim of this research was to explore the value of hsa_circ_0002320 as a potential diagnostic biomarker for CRC prognosis. Plasma samples, CRC tissues, and adjacent normal tissues were obtained from 50 patients with CRC, before any treatment, and 100 plasma samples were acquired from healthy individuals. Hsa_circ_0002320 levels in these samples were analyzed by reverse transcription-quantitative polymerase chain reaction. Correlations between hsa_circ_0002320, clinicopathological characteristics, and overall survival (OS) of CRC patients were also investigated. Receiver-operating characteristic (ROC) curve analysis was used to assess the value of hsa_circ_0002320 for CRC diagnosis. Finally, a bioinformatics analysis was performed to verify the effect of hsa_circ_0002320 on CRC prognosis. Expression levels of hsa_circ_0002320 were significantly decreased in CRC plasma ( P < .05). The expression level of hsa_circ_0002320 was significantly correlated with OS time ( P < .05). Higher hsa_circ_0002320 reflected significantly greater OS; the HR of high hsa_circ_0002320 was 0.161 (95% CI, 0.066–0.393; P = .000). The area under the ROC curve of hsa_circ_0002320 in CRC was 0.823, which was higher than for the carcinoembryogenic antigen (area under the curve = 0.764). Kaplan-Meier analysis showed that CRC patients with low expression of hsa_circ_0002320 exhibited poorer OS times than those with high expression. Hsa_circ_0002320 could be a novel, noninvasive diagnostic blood biomarker for CRC prognosis.

The circular RNA circSPARC enhances the migration and proliferation of colorectal cancer by regulating the JAK/STAT pathway

“…Therefore, there is a clinical need for an improved tumor biomarker for the diagnosis of CRC. Compare to some other researches of circRNAs, hsa_circ_0002320 has higher sensitivity and specificity for the diagnosis of CRC [ 22 – 24 ]. With the development of liquid biopsy tools and other clinical techniques [ 25 , 26 ], circSPARC is expected to be a new biomarker for the prognosis and early diagnosis of CRC.…”

Prognostic significance of hsa_circ_0048122 to predict liver metastasis in early‐stage colorectal cancer

“… 26 Similar biomarkers were outlined for gastric cancer using circRNA microarray profiling, 27 such as hsa_circ_0001020 for screening and prognosis of this malignancy. 28 Similarly, circRNAs have also been widely used as markers in CRC diagnosis, including hsa_circ_0002320, 29 hsa_circ_001659, 30 hsa_circ_0004585, 31 circ_0026344, 32 and hsa_circ_0001649. 33 However, biomarkers for CRCLM diagnosis are not fully comprehended.…”

Epigenetic Landscape of Liquid Biopsy in Colorectal Cancer

“…Of note, other studies have proposed different combinations of circulating lncRNAs as diagnostic biomarkers for the detection of CRC and precancerous lesions (Shi et al, 2015;. In addition to lncRNAs, the analysis of circRNAs in blood, as biomarkers with relevant clinical properties for CRC diagnosis and prognosis, has raised considerable interest (Lin et al, 2019;Yang N. et al, 2020).…”